IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 84.78

Change

-0.64 (-0.75)%

Market Cap

N/A

Volume

0.14M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.46 (-1.09%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-0.72 (-1.14%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-0.71 (-0.71%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-0.27 (-0.33%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.43 (-2.19%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.52 (-0.53%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.69 (-2.47%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.45 (-1.68%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.19 (-2.16%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.27 (-1.54%)

USD 0.01B

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.99 % 0.00 %

-0.15 (-0.11%)

USD 1.47B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

-0.84 (-0.11%)

CAD 0.56B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.38% 86% B+ 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.38% 86% B+ 48% F
Trailing 12 Months  
Capital Gain -7.48% 38% F 28% F
Dividend Return 1.41% 100% F 29% F
Total Return -6.07% 48% F 25% F
Trailing 5 Years  
Capital Gain 25.12% 62% D 46% F
Dividend Return 8.07% 89% A- 18% F
Total Return 33.19% 62% D 38% F
Average Annual (5 Year Horizon)  
Capital Gain 4.19% 71% C- 52% F
Dividend Return 5.14% 71% C- 47% F
Total Return 0.95% 74% C 23% F
Risk Return Profile  
Volatility (Standard Deviation) 12.42% 76% C+ 72% C
Risk Adjusted Return 41.40% 81% B- 57% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike